福莱德瑞克运动失调症（FA）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 德国市场预计将从 2025 年的约 4,500 万美元成长到 2035 年的约 1.35 亿美元（年复合成长率约 11-12%）。
• 目前的疗法仍有许多未满足的需求，而新的疾病修正治疗和基因标靶治疗的出现正在推动成长。

福莱德瑞克运动失调症（FA）概述

福莱德瑞克运动失调症是一种罕见的体染色体隐性遗传性神经退化性疾病。最常见的原因是FXN基因内含子1中GAA三核苷酸重复序列的纯合扩增，导致frtaxin蛋白表现降低。此病通常在儿童或青春期发病，但少数患者表现为25岁以后发病的晚期髮型。

Frataxin 缺乏会导致粒线体铁硫丛集酶活性降低、粒线体内铁累积、氧化压力和细胞内能量产生受损，最终导致进行神经退化和心肌病。

临床上，患者会出现进行进行性共济失调、构音障碍、感觉神经病变、深部肌腱反射消失、脊椎和肥厚型心肌病。其他系统性症状，例如糖尿病，也可能出现，但认知功能相对保留。大多数病例是由GAA重复序列扩增引起的，但FXN基因的点突变也可导致复合杂合子患病。

从流行病学角度来看，FRDA 在欧洲血统的人群中更为常见，但在世界各地的所有种族群体中都有发现。

主要亮点

• FRDA 是一种罕见的进行性神经肌肉疾病，会造成严重的神经系统和心臟负担。
• 预计美国患有该疾病的人数将从 2025 年的约 8,600 人增加到 2035 年的约 9,300 人（年复合成长率约为 0.7%）。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴疗法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• PTC Therapeutics
• Design Therapeutics, Inc.
• Larimar Therapeutics, Inc.
• Biogen
• Lexeo Therapeutics
• Solid Biosciences Inc.

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前疗法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要疗法概述及KOL洞察
• 新兴疗法
  • 重点
  • 值得关注的后期新疗法—概述、市场上市预期和KOL洞察
  • 值得关注的早期管道

第六章：未满足的需求与目标产品分析

• 主要未满足的需求以及透过新兴疗法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Friedreich Ataxia (FA) Market Outlook

Thelansis's "Friedreich Ataxia (FA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Friedreich Ataxia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Friedreich Ataxia (FA) Overview

Friedreich ataxia is a rare autosomal recessive neurodegenerative disorder most commonly caused by homozygous GAA trinucleotide repeat expansions in intron 1 of the FXN gene, which reduce frataxin expression. Typical onset is in childhood or adolescence, although a minority of patients present with late-onset disease after age 25.

Frataxin deficiency leads to impaired mitochondrial iron-sulfur cluster enzyme activity, mitochondrial iron accumulation, oxidative stress, and disrupted cellular energy production, ultimately driving progressive neurodegeneration and cardiomyopathy.

Clinically, patients develop progressive gait ataxia, dysarthria, sensory neuropathy, loss of deep tendon reflexes, scoliosis, and hypertrophic cardiomyopathy. Additional systemic manifestations such as diabetes may occur, while cognitive function is relatively preserved. Although most cases result from GAA expansions, FXN point mutations can also cause disease in compound-heterozygous states.

Epidemiologically, FRDA is more prevalent in populations of European ancestry but is observed globally across ethnic groups.

Key Highlights

• FRDA is a rare, progressive neuromuscular disorder with significant neurological and cardiac burden
• US prevalence is expected to increase from ~8.6K in 2025 to ~9.3K by 2035 (~0.7% CAGR)

Market Overview

• Germany market is projected to grow from ~$45M in 2025 to ~$135M by 2035 (~11-12% CAGR)
• Growth driven by emerging disease-modifying and gene-targeted therapies, with high unmet need in current care

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• PTC Therapeutics
• Design Therapeutics, Inc.
• Larimar Therapeutics, Inc.
• Biogen
• Lexeo Therapeutics
• Solid Biosciences Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)